StartupHistory

An open directory of startups through time

Public records · dated sources
Free to read. Free to reuse.

Company records / amolytpharma.com

Amolyt Pharma

Amolyt Pharma (amolytpharma.com): 1 change recorded in its website history since July 2020.

The website did not answer the latest live check. Last tried 6 November 2026.

Recorded changes

Newest observations first. Each interval bounds when the website changed; it is not an exact event date.

  1. HiringBetween and

    Added a careers page.

    Observed on the company’s website; business claims are not independently verified.

    earlier archived pagelater archived pageLink to observation

First recorded website

Observed 6 July 2020

Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.

How it described itself

Advancing peptides for the treatment of rare endocrine and metabolic disorders

We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.

Homepage

Displayed as investors on the website
LSP · Novo Holdings · Kurma Partners · OrbiMed · Pontifax · Partners Healthcare · bpifrance · Turenne · sham partageons plus · CA · SofiMAC · initiative OCTALFA · Kreaxi
Funding statements on the website
inception, Alizé Pharma 3, now Amolyt Pharma, has raised 3.3 M€ ($3.6 M) in seed funding, followed by a 67 M€ ($74 M) Series A financing from a strong international syndicate of investors.

archived pageLink to first observation

All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.

How it describes itself

Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.

  1. July 2020 – August 2024 · 10 captures · latest observed messagingAdvancing peptides for the treatment of rare endocrine and related diseases

    We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.

    This wording observed 10 August 2024.

    archived page
    Inspect 10 captures in this group
    • 6 July 2020 · Advancing peptides for the treatment of rare endocrine and metabolic disorders archived page
    • 18 January 2021 · Advancing peptides for the treatment of rare endocrine and metabolic disorders archived page
    • 3 August 2021 · Advancing peptides for the treatment of rare endocrine and metabolic disorders archived page
    • 31 January 2022 · Advancing peptides for the treatment of rare endocrine and related diseases archived page
    • 2 July 2022 · Advancing peptides for the treatment of rare endocrine and related diseases archived page
    • 6 January 2023 · Advancing peptides for the treatment of rare endocrine and related diseases archived page
    • 3 July 2023 · Advancing peptides for the treatment of rare endocrine and related diseases archived page
    • 4 January 2024 · Advancing peptides for the treatment of rare endocrine and related diseases archived page
    • 3 July 2024 · Advancing peptides for the treatment of rare endocrine and related diseases archived page
    • 10 August 2024 · Advancing peptides for the treatment of rare endocrine and related diseases archived page

Cite this record

StartupHistory, “Amolyt Pharma” company record, https://startuphistory.org/c/amolytpharma.com

Machine-readable: /c/amolytpharma.com.json. How changes are found: method.